Macrogenics (MGNX) Cash & Equivalents (2012 - 2026)

Macrogenics (MGNX) has 15 years of Cash & Equivalents data on file, last reported at $66.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 54.31% year-over-year to $66.5 million in Q1 2026; TTM through Mar 2026 was $66.5 million, a 54.31% decrease from a year earlier, with the FY2025 full-year figure at $57.2 million, down 68.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $66.5 million, up from $57.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MGNX reached as high as $224.3 million in Q1 2023 and fell as low as $21.5 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $105.4 million across 5 years, with a median of $89.9 million in 2023.
• Across the five-year window, Cash & Equivalents plunged 88.64% in 2022 and soared 406.58% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $108.9 million in 2022, then dropped by 7.28% to $101.0 million in 2023, then jumped by 81.11% to $182.8 million in 2024, then tumbled by 68.71% to $57.2 million in 2025, then climbed by 16.25% to $66.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $66.5 million in Q1 2026, $57.2 million in Q4 2025, and $80.1 million in Q3 2025.